Bimiralisib

DRUG3 trials

Sponsors

PIQUR Therapeutics AG, M.D. Anderson Cancer Center, TORQUR

Conditions

Actinic KeratosisHNSCCLymphoma, Malignant

Phase 2

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

CompletedNCT02249429

PIQUR Therapeutics AGLymphoma, Malignant

Start: 2015-05-31End: 2018-09-11Updated: 2019-09-06

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

TerminatedNCT03740100

M.D. Anderson Cancer CenterHNSCC

Start: 2019-01-25End: 2020-12-09Updated: 2023-07-14

Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

CompletedNCT06319794

TORQURActinic Keratosis

Start: 2024-04-02End: 2025-06-24Updated: 2025-07-18

Related Papers

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function <i>NOTCH1</i>-Mutant Head and Neck Cancer

The Oncologist2022-09-1621 citations

Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring <i>NOTCH1</i> loss of function (LOF) mutations.

Journal of Clinical Oncology2020-05-206 citations

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Molecular Cancer Therapeutics2019-12-017 citations

Highlights of This Issue

Clinical Cancer Research2019-06-01

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

Blood2016-12-02

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

Blood2015-12-031 citations

Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas

Molecular Cancer Therapeutics2015-12-01